Amgen And Servier Extend Omecamtiv Mecarbil Collaboration In Chronic Heart Failure

Servier Provides Notice to Exercise Commercialization Option in Europe and Commonwealth of Independent States, Including Russia THOUSAND OAKS, Calif. and SURESNES, France, Sept. 1, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Servier today announced an advancement in their cardiovascular collaboration, with Servier's decision to exercise its option to commercialize omecamtiv mecarbil in chronic heart failure in Europe, as well in as the Commonwealth of Independent States, including Russia, which were added to the collaboration. The companies also announced the omecamtiv mecarbil Phase 3 development program will move forward in collaboration with Cytokinetics. Under the terms of the a...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news